Newer products drove strong increases in second quarter earnings for Amgen. The Thousand Oaks biotech giant also announced that two key executives are leaving the company and it has made steps toward continuing to fill its pipeline with new early stage investments. A $1.32 per share dividend is also slated for September after the company…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
